Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Dec 7, 2016
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial.  Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). The study enrolled approximately 60 pa...
Nov 30, 2016
SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference on Friday, December 9 at 6:00pm ET.  The conference is taking place December 8-10 at the Walt D...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 at 1:30pm ET.  The conference will take place November 29-30, 2016 a...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am CT.  The scientific sessions are taking place November 12-16, 2016 in New Orleans, Louisiana at the Ern...
Nov 7, 2016
SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the third quarter ended September 30, 2016, and provided a corporate update. "This was a highly productive quarter for Arena.  We continue to make significant progress focusing the company on our unpartnered clinical p...
Nov 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin HCl) CIV. Hosted by The Obesity Society and the American Society for Metabolic and Bari...
Oct 31, 2016
SAN DIEGO, Oct. 31, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2016 financial results and provide a corporate update on Monday, November 7, 2016, after the close of the U.S. financial markets.  The Company will host a conference call and live webcast with the inve...
Oct 11, 2016
SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET.  The meeting is taking place October 15-19 in Vienna, Austria.  The dat...
Oct 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. "With more than 7...
Sep 1, 2016
SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"), an independent, privately-held drug discovery incubator.  Beacon will focus on identifying and advancing molecules targeting G-Protein Coupled Receptors (GCPRs) from concept to clinic leverag...
Aug 15, 2016
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today.  Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.    "I am excited to have Vince join u...
Aug 8, 2016
SAN DIEGO, Aug. 8, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update. "We are continuing to successfully execute the turnaround and transition of Arena from a historically research-oriented organization to a high perfor...
Aug 1, 2016
SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets.  The Company will host a conference call and live webcast with the invest...
Jul 19, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets. The new formulation of lorcaserin will offer...
Jul 14, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 14, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI® (lorcaserin HCl: U.S. brand name: BELVIQ...
Page:
...
Next Last
 
= add release to Briefcase